Position in ANAB
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$2,886,367
+$494,934 QoQ
Shares Held
42,761
-33.9% QoQ
Ownership
0.147%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#61
of 211 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ANAB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Bleakley Financial Group, LLC holds $23,738,174 across 21 Biotechnology names. ANAB ranks #2 (12.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
18,400 | $9,139,832 | |
| 2 | ANAB |
Anaptysbio, Inc
This page
|
42,761 | $2,886,367 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
|
12,538 | $1,536,908 | |
| 4 | IONS |
Ionis Pharmaceuticals Inc
|
14,793 | $1,172,936 | |
| 5 | IBRX |
ImmunityBio, Inc.
|
129,381 | $1,132,730 | |
| 6 | CORT |
Corcept Therapeutics Inc
|
11,638 | $1,011,924 | |
| 7 | BCAX |
Bicara Therapeutics Inc.
|
29,181 | $866,383 | |
| 8 | RPRX |
Royalty Pharma plc
|
14,626 | $820,079 |
All Filings in ANAB
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,886,367 | 42,761 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $2,391,433 | 43,120 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $2,111,158 | 43,547 | Shares | Sole | 2026-02-09 | |
| 2025-09-30 | $1,224,216 | 39,981 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $833,632 | 37,551 | Shares | Sole | 2025-07-30 | |
| No filing history on record for this holder in this stock. | ||||||